Navigation Links
Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
Date:6/1/2009

fety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the SEC on May 11, 2009, as well as other filings by the company with the SEC.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
2. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
3. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
4. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
5. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
6. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
7. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
8. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
9. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
10. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
11. Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Aytu BioScience, Inc. (OTCQB: AYTU), a specialty ... related conditions, announced today that it has closed the ... financing, raising a total of $5.175 million, which includes ... Josh Disbrow , Chief Executive Officer ... intended to be used to conduct clinical studies for ...
(Date:9/2/2015)... 2, 2015 BioLight Life ... the "Company"), a firm that invests in, manages ... diagnostics, announced today that presentations highlighting its IOPtiMate™ ... delivered at the Ophthalmology Futures European Forum and ... Cataract & Refractive Surgeons ("ESCRS"), both taking place ...
(Date:9/2/2015)... 2, 2015 Biovista Inc. ... BeHEARD von 2015 bekanntgeben zu können. Hierbei handelt ... Institute. Biovista unterstützt mit seiner Möglichkeit ... Behandlung anderer Krankheiten als denen, für die ein ... und sein Team bei der Wylder Nation Foundation ...
(Date:9/2/2015)... NJ (PRWEB) , ... September 02, 2015 , ... ... Technical Services Staff members will be attending Pharma Ed Resources upcoming educational ... respected group of industry leading speakers, this timely conference will provide Updates & ...
Breaking Biology Technology:Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3
(Date:8/26/2015)... PUNE, India , August 26, 2015 ... (Two, Three, Four, and Five Factor), Application (Travel & ... and Geography - Global Forecast to 2020", published by ... 9.60 Billion by 2020, growing at a CAGR of ... 71 Tables and 82 F igures spread through ...
(Date:8/20/2015)... , Aug. 20, 2015 The ... consumers that are active and healthy. However, wearable ... the hospital environment to help improve diagnostic capabilities ... video from the Wearable Technologies Conference 2015 ... new applications for wearables in healthcare.    ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... treated like any other animal depending on where the owners ... Department of Sociology and Anthropology at Indiana University South Bend, ... to have a city background. "To think of pets ... Blouin said, "which makes sense given the utilitarian relationships people ...
... a new, rapid and less expensive DNA sequencing strategy, ... cases of Kabuki syndrome, a rare disorder that causes ... the entire human genome, the new approach sequences just ... that contains protein-coding genes. Kabuki syndrome, which ...
... DigitalPersona, Inc., a global provider of ... that Memorial Hospital of Union County, Marysville, ... protection suite to help meet the Health ... for secure access to electronic health records ...
Cached Biology News:Dogs' family status depends on family's locale 2Discovered gene causes Kabuki syndrome 2Discovered gene causes Kabuki syndrome 3Memorial Hospital Selects DigitalPersona Pro to Enhance HIPAA Security 2Memorial Hospital Selects DigitalPersona Pro to Enhance HIPAA Security 3
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
Src cDNA Expression Kit (wild type)...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Biology Products: